VRDN
Viridian Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.48B
P/E Ratio
—
EPS
$-3.32
Beta
1.17
52W High
$34.29
52W Low
$11.11
50-Day MA
$28.35
200-Day MA
$24.45
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.01
PEG Ratio
—
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Fundamentals
| Revenue (TTM) | $70.85M |
| Gross Profit (TTM) | $-268.08M |
| EBITDA | $-362.94M |
| Operating Margin | -95643.00% |
| Return on Equity | -49.20% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $0.83 |
| Book Value | $5.79 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | 20.87 |
| EV/Revenue | 17.38 |
| EV/EBITDA | -3.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83.30% |
| Shares Outstanding | $102.21M |
| Float | $102.15M |
| % Insiders | 0.15% |
| % Institutions | 108.76% |
Analyst Ratings
Consensus ($35.59 target)
3
Strong Buy14
Buy1
HoldData last updated: 4/9/2026